Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

GARP and CTLA4 identify a potently suppressive antigen specific Treg population in demyelinating autoimmunity 3183

View through CrossRef
Abstract Description   In demyelinating disease, Tregs with the most effective suppressive capacity are self-antigen specific; however, it is unclear how the parameters of self-antigen stimulation (affinity, force, and bond lifetime) modulate suppressive potency. A critical unmet need limiting these studies is the ability to isolate antigen specific Tregs without prior knowledge of TCR reactivity. Here, we utilize the well-described myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide driven experimental autoimmune encephalomyelitis (EAE) in B6 mice and have identified GARP and CTLA4 as markers that predict Treg antigen reactivity. In this system, we show that tetramer staining in the spleen is increased in enriched GARP+ CTL4+ Tregs (30%) compared to bulk Tregs (10%). We found that GARP+ CTLA4+ Tregs are more potent antigen specific suppressors by in vitro suppression assay using 2D2 responders stimulated with MOG. We compared bond lifetime and found that peak bond lifetime shifted to higher force in CTLA4+ GARP+ Tregs. We hypothesized that trogocytosis may be a force dependent mechanism of suppression by removal of self-antigen and we found that CTLA4+ GARP+ Tregs pulled more MOG loaded MHCII from the surface of antigen presenting cells than CTLA4- Tregs. This research uncovers an understanding of surface markers that will identify potently suppressive antigen specific Tregs, which will allow the design of therapeutic strategies for Tregs in autoimmune conditions. Funding Sources NIH 5R01AI169835-03 NIH 5T32NS115664-03 Topic Categories Therapeutic Approaches to Autoimmunity (THER)
Title: GARP and CTLA4 identify a potently suppressive antigen specific Treg population in demyelinating autoimmunity 3183
Description:
Abstract Description   In demyelinating disease, Tregs with the most effective suppressive capacity are self-antigen specific; however, it is unclear how the parameters of self-antigen stimulation (affinity, force, and bond lifetime) modulate suppressive potency.
A critical unmet need limiting these studies is the ability to isolate antigen specific Tregs without prior knowledge of TCR reactivity.
Here, we utilize the well-described myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide driven experimental autoimmune encephalomyelitis (EAE) in B6 mice and have identified GARP and CTLA4 as markers that predict Treg antigen reactivity.
In this system, we show that tetramer staining in the spleen is increased in enriched GARP+ CTL4+ Tregs (30%) compared to bulk Tregs (10%).
We found that GARP+ CTLA4+ Tregs are more potent antigen specific suppressors by in vitro suppression assay using 2D2 responders stimulated with MOG.
We compared bond lifetime and found that peak bond lifetime shifted to higher force in CTLA4+ GARP+ Tregs.
We hypothesized that trogocytosis may be a force dependent mechanism of suppression by removal of self-antigen and we found that CTLA4+ GARP+ Tregs pulled more MOG loaded MHCII from the surface of antigen presenting cells than CTLA4- Tregs.
This research uncovers an understanding of surface markers that will identify potently suppressive antigen specific Tregs, which will allow the design of therapeutic strategies for Tregs in autoimmune conditions.
Funding Sources NIH 5R01AI169835-03 NIH 5T32NS115664-03 Topic Categories Therapeutic Approaches to Autoimmunity (THER).

Related Results

Abstract 1644: Generation and validation of humanized GARP mice for testing novel anti-human GARP antibodies
Abstract 1644: Generation and validation of humanized GARP mice for testing novel anti-human GARP antibodies
Abstract GARP is a type I transmembrane protein expressed on regulatory T cells (Tregs) and platelets. GARP expression has been shown to play an important role in th...
Abstract 1847: Anti-GARP antibody DS-1055a augments antitumor immunity by depleting highly suppressive GARP+ regulatory T cells
Abstract 1847: Anti-GARP antibody DS-1055a augments antitumor immunity by depleting highly suppressive GARP+ regulatory T cells
Abstract Immune checkpoint blockers (ICBs) have drastically changed the clinical care of cancer; however, the population of patients who can benefit is relatively sm...
Abstract 1497: Identification of discrepancy between CTLA4 expression and CTLA4 activation in gastric cancer
Abstract 1497: Identification of discrepancy between CTLA4 expression and CTLA4 activation in gastric cancer
Abstract Objective: Recently, immune checkpoints blockers showed higher anti-tumor activity for advanced gastric cancer (GC). The purpose of the study is to find ...
Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFβ gene variants
Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFβ gene variants
AbstractBackgroundCD4+CD25+regulatory T cells play an essential role in maintaining immune homeostasis and preventing autoimmunity. Therefore, defects in Treg development, maintena...
Treg suppressor function within allografts is required for tolerance
Treg suppressor function within allografts is required for tolerance
Abstract The role of regulatory CD4+Foxp3+ T cells (Treg) suppressor function within allografts in tolerance remain unclear. To directly address this, we first used ...
GARP: A Key Target to Evaluate Tumor Immunosuppressive Microenvironment
GARP: A Key Target to Evaluate Tumor Immunosuppressive Microenvironment
Glycoprotein-A repetitions predominant (GARP) is the docking receptor for latent transforming growth factor (LTGF-β) and promotes its activation. In cancer, increased GARP expressi...

Back to Top